From mboxrd@z Thu Jan 1 00:00:00 1970 From: "Deana Bermudez" Subject: AFTER-HOURS TRADING - Breaking News...dex Date: Thu, 04 Dec 2003 01:25:53 -0600 Sender: acpi-devel-admin-5NWGOfrQmneRv+LV9MX5uipxlwaOVQ5f@public.gmane.org Message-ID: Reply-To: "Deana Bermudez" Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="19D54DEF._5.4..5AE_" Return-path: Errors-To: acpi-devel-admin-5NWGOfrQmneRv+LV9MX5uipxlwaOVQ5f@public.gmane.org List-Unsubscribe: , List-Post: List-Help: List-Subscribe: , List-Archive: To: gabai-penyumbang-5NWGOfrQmneRv+LV9MX5uipxlwaOVQ5f@public.gmane.org Cc: acpi-devel-5NWGOfrQmneRv+LV9MX5uipxlwaOVQ5f@public.gmane.org List-Id: linux-acpi@vger.kernel.org --19D54DEF._5.4..5AE_ Content-Type: text/plain; Content-Transfer-Encoding: quoted-printable AFTER-HOURS TRADING - BREAKING NEWS Get Quote - http://quote.money.cnn.com/quote/quote?symbols=3Dhtds Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tuberci= n Toxicity Study and Formation of Scientific Advisory Panel - Wednesday De= cember 3, 8:04 pm ET DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases = Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for= the independent medical group conducting the testing for HTTD (HTDS) has = forwarded the formal Testing Results of Tubercin=AE's Toxicity Trials to H= TTD. Tubercin of five different concentrations was administered to five groups = of mice. A pathologist at the University of Oklahoma Health Science Center= performed autopsies. The mice were randomized and only the control mouse = was known to the pathologist, as stated in the cover letter of the Patholo= gy Report. The report concludes, "All tissues evaluated, visceral organs and the brai= n were essentially normal in appearance." "The importance of this report i= s even better than I expected," stated the spokesperson for the medical gr= oup. "As the testing continues and if the results are similar to those of = Chemotherapy and or radiation with no harmful side effects, Tubercin has e= normous potential for the treatment of cancer and the immune system." The President and CEO of HTTD, Mr. Colm J. King is in the process of formi= ng a Scientific Advisory Panel with leading Oncologists and Immunologists = from prestigious institutions in the U.S. The panel will review the report= s and results of Tubercin=AE's findings and will report back to Mr. King w= ith the ongoing reports in layman language for the shareholders. "We are continuing to receive promising results regarding Tubercin=AE and = we're looking forward to additional positive results in the near future," = stated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is t= he first step on the way to human clinical trials as well as the first pos= itive breakthrough conducted in the United States with an independent medi= cal group for Tubercin=AE. Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate= d ("HTTD") holds the international marketing rights, except South Korea, t= o Tubercin=AE, a patented immunostimulant developed for combating Cancer u= nder medical patent (US Patent 6,274,356). The unique properties unlike ot= her cancer products are clearly stated in the abstract summary of the pate= nt... "A carbohydrate complex, which is a mixture of low molecular-weight = polysaccharides of an arabinomannan structure extracted from Mycobacterium= tuberculosis, is highly effective in treating various cancer patients wit= hout incurring any adverse side effects." Statements in this press release that are not historical facts are forward= -looking statements within the meaning of the Securities Act of 1933, as a= mended. Those statements include statements regarding the intent, belief o= r current expectations of the Company and its management. Such statements = reflect management's current views, are based on certain assumptions and i= nvolve risks and uncertainties. Actual results, events, or performance may= differ materially from the above forward-looking statements due to a numb= er of important factors, and will be dependent upon a variety of factors, = including, but not limited to, our ability to obtain additional financing = and access funds from our existing financing arrangements that will allow = us to continue our current and future operations and whether demand for ou= r product and testing service in domestic and international markets will c= ontinue to expand. The Company undertakes no obligation to publicly update= these forward-looking statements to reflect events or circumstances that = occur after the date hereof or to reflect any change in the Company's expe= ctations with regard to these forward-looking statements or the occurrence= of unanticipated events. djexkywzj fhgi r zmwq fz ddlncrzbx rozqks --19D54DEF._5.4..5AE_-- ------------------------------------------------------- This SF.net email is sponsored by: SF.net Giveback Program. Does SourceForge.net help you be more productive? Does it help you create better code? SHARE THE LOVE, and help us help YOU! Click Here: http://sourceforge.net/donate/